2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
4
Active Trials
200 recruiting
6
Rare Diseases
across 17 areas
0
News (30d)
Quiet
PersonGen BioTherapeutics (Suzhou) Co. Ltd. is a company with 2 orphan drug designations across 6 rare diseases. Active clinical trials in 4 indications. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute lymphoblastic leukemia | Chimeric Antigen Receptor T Cells targeting CD7 | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| malignant carotid body paraganglioma | Autologous chimeric antigen receptor (CAR) T cells targeting B7-H3 | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | Autologous chimeric antigen receptor (CAR) T cells targeting B7-H3 | Des.TrialAppr. |
| treatment-refractory schizophrenia | Autologous chimeric antigen receptor (CAR) T cells targeting B7-H3 | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
113
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
113
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
1
affecting portfolio